Gilead Sciences, Inc. (GILD) reported better-than-expected results in the second quarter and raised its annual earnings guidance.Adjusted earnings per share (EPS) of 2.01comfortablybeattheZacksConsensusEstimateof1.61. In the year-ago quarter, the company reported adjusted earnings of 1.34pershare.Theyear−over−yearincreasewasdrivenbyhigherrevenuesandloweroperatingexpenses.Totalrevenuesof6.9 billion beat the Zacks Consensus Estimate of $6.6, primarily due to high HIV, oncology and ...